Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Recruiting

Phase 1

T-Cells with VaccineAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06253520

Conditions

Metastatic Solid Cancers

Colorectal Cancer

Breast Cancer

Non-Small Cell Lung Cancer

Gastrointestinal Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Aldesleukin

Fludarabine

Cyclophosphamide

KRAS TCR-Transduced PBL

GRT-C903/GRT-R904

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-14. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-10-23.